Page 63 - Amgen News Today

Intelligence Driven Advisers LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,649 shares of the medical research company’s stock after purchasing an additional 158 shares during the quarter. Intelligence Driven Advisers LLC’s holdings in Amgen were worth […]

Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.

Amgen stock dipped late Thursday despite beating first-quarter expectations. The company is running a midstage study of its obesity drug. The post Amgen Beats…

Higher futures point to a positive start for U.S. stocks Thursday morning. The market is likely to benefit from Fed Chair Jerome Powell's comments that the next rate move from the central bank will most likely be an interest rate reduction.

These are the stocks posting the largest moves in extended trading.

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.

The major averages are on track for modest declines on the week as Wall Street awaits the April jobs report.

Stocks in Toronto gained strength by the end of the Thursday session, following up on the good vibes given off by Bank of Canada Tiff Macklem that interest rates are not likely to jump any time soon. The TSX Composite recovered 94.67 points to ...

By Paul Ziobro Amgen posted higher revenue, but swung to a first-quarter loss, driven by a drop in value of its investment in BeiGene and other expenses from its Horizon Therapeutics...

Cary Street Partners Investment Advisory LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 86.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,190 shares of the medical research company’s stock after selling 7,464 shares during […]